1-(8-Methoxy-4-o-tolylamino-quinolin-3-yl)-butan-1-one

ID: ALA327717

Cas Number: 115607-61-9

PubChem CID: 3081087

Max Phase: Preclinical

Molecular Formula: C21H22N2O2

Molecular Weight: 334.42

Molecule Type: Small molecule

Names and Identifiers

Synonyms: SK&F-96067 | SK-96067 | 115607-61-9|SKF96067|Skf-96067|3-Butyryl-4-(2-methylphenylamino)-8-methoxyquinoline|SK&F-96067|CHEMBL327717|SK-96067|1-Butanone, 1-[8-methoxy-4-[(2-methylphenyl)amino]-3-quinolinyl]-|SK&F 96067|1-Butanone, 1-(8-methoxy-4-((2-methylphenyl)amino)-3-quinolinyl)-|MAVJDLHBPIXVJL-UHFFFAOYSA-N|1-[8-methoxy-4-(2-methylanilino)quinolin-3-yl]butan-1-one|SCHEMBL451221|DTXSID40151146|BDBM50001254|HY-U00042|AKOS030618286|CS-6768|SB72126|3-butyryl-8-methoxy-4-[(2-methylphenyl)amino]quiShow More⌵

Canonical SMILES:  CCCC(=O)c1cnc2c(OC)cccc2c1Nc1ccccc1C

Standard InChI:  InChI=1S/C21H22N2O2/c1-4-8-18(24)16-13-22-21-15(10-7-12-19(21)25-3)20(16)23-17-11-6-5-9-14(17)2/h5-7,9-13H,4,8H2,1-3H3,(H,22,23)

Standard InChI Key:  MAVJDLHBPIXVJL-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 25 27  0  0  0  0  0  0  0  0999 V2000
    3.2042   -5.4042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9167   -5.8125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4917   -5.8167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2042   -4.5792    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2000   -7.0542    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.4917   -6.6375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9167   -6.6417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4875   -4.1667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6292   -5.4000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7792   -7.0500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.6292   -4.5750    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.4875   -3.3417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7792   -5.4125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7875   -7.8750    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.0667   -5.8167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7667   -4.5792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3500   -5.8042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0750   -6.6417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2000   -2.9250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7667   -2.9292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0667   -8.2917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0625   -5.3917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0542   -4.1667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7792   -5.8042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0542   -3.3417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  1  1  0
  4  1  1  0
  5  6  1  0
  6  3  1  0
  7  2  1  0
  8  4  1  0
  9  2  1  0
 10  6  2  0
 11  9  2  0
 12  8  1  0
 13  3  2  0
 14 10  1  0
 15 13  1  0
 16  8  2  0
 17  9  1  0
 18 15  2  0
 19 12  1  0
 20 12  2  0
 21 14  1  0
 22 17  1  0
 23 16  1  0
 24 22  1  0
 25 23  2  0
  5  7  2  0
 10 18  1  0
 25 20  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA327717

   3-Butyryl-4-(2-methylphenylamino)-8-methoxyquinoline

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 334.42

Molecular Weight (Monoisotopic): 334.1681

AlogP: 5.28

#Rotatable Bonds: 6

Polar Surface Area: 51.22

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: ┄

CX Basic pKa: 4.52

CX LogP: 5.93

CX LogD: 5.93

Aromatic Rings: 3

Heavy Atoms: 25

QED Weighted: 0.62

Np Likeness Score: -0.99

References

1. Leach CA, Brown TH, Ife RJ, Keeling DJ, Parsons ME, Theobald CJ, Wiggall KJ..  (1995)  Reversible inhibitors of the gastric (H+/K+)-ATPase. 4. Identification of an inhibitor with an intermediate duration of action.,  38  (14): [PMID:7629813] [10.1021/jm00014a026]

2. Ife RJ, Brown TH, Blurton P, Keeling DJ, Leach CA, Meeson ML, Parsons ME, Theobald CJ..  (1995)  Reversible inhibitors of the gastric (H+/K+)-ATPase. 5. Substituted 2,4-diaminoquinazolines and thienopyrimidines.,  38  (14): [PMID:7629814] [10.1021/jm00014a027]

3. Yum EK, Kang SK, Kim SS, Choi JK, Cheon HG..  (1999)  Synthesis and pharmacological profile of 1-aryl-3-substituted pyrrolo[3,2-c]quinolines.,  9  (19): [PMID:10522698] [10.1016/s0960-894x(99)00496-5]

4. Ife RJ, Brown TH, Keeling DJ, Leach CA, Meeson ML, Parsons ME, Reavill DR, Theobald CJ, Wiggall KJ..  (1992)  Reversible inhibitors of the gastric (H+/K+)-ATPase. 3. 3-substituted-4-(phenylamino)quinolines.,  35  (18): [PMID:1326634] [10.1021/jm00096a018]

Source

Source(1):

• Scientific Literature